Reuters logo
BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid
October 30, 2017 / 10:59 AM / a month ago

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

Oct 30 (Reuters) - Celgene Corp

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett - ‍subject to FDA approval of co’s ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​

* Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below